Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Issue : PJ December 2015 online

Sort by: Newest first Oldest first A-Z Z-A

  • Healthcare professionals can reduce inappropriate prescribing of drugs in older people who are taking four or more medicines which has the potential for negative outcomes. In the image, a woman holds multiple medicines in her hand

    Interventions by health staff can cut inappropriate prescribing, study finds Subscription

    18 DEC 2015 15:25 By Debbie Andalo

    Healthcare professionals can reduce inappropriate prescribing of drugs in older people who are taking four or more medicines, finds a study published in BMJ Open.

  • A new rescue treatment, uridine triacetate, for patients accidentally given an overdose of chemotherapy has been approved by the US FDA. In the image, a cancer patient receives chemotherapy treatment

    FDA approves uridine triacetate as chemotherapy overdose rescue Subscription

    18 DEC 2015 14:37

    A new rescue treatment for patients accidentally given an overdose of chemotherapy has been approved by the US Food and Drug Administration.

  • Local practice forum event: 13 January 2016 Subscription

    17 DEC 2015 16:02

    Wednesday 13 January: Gloucestershire Local practice forum event, ‘Pharmacist Support’. Sandford Education Centre, Keynsham Road, Cheltenham GL53 7PX. Buffet 6.30pm, event 7.30pm. Contact by 6pm on Wednesday 6 January to book food.

  • Cosentyx licence extension Subscription

    17 DEC 2015 16:00

    Cosentyx (secukinumab; Novartis) has been granted a licence for two new indications. It can now be used for the treatment of active ankylosing spondylitis and used alone or in combination with methotrexate for treatment of active psoriatic arthritis, both in adults who have responded inadequately to conventional therapy. 

  • Xalkori approved for first-line use Subscription

    17 DEC 2015 15:50

    The European Commission has approved the use of Xalkori (crizotinib; Pfizer) for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer. The drug was previously only licensed for second-line treatment. 

  • Discontinued oral contraceptives from Janssen Subscription

    17 DEC 2015 15:44

    Janssen has taken the decision to discontinue the following oral contraceptive 3x21 strip packets: Trinovum (norethisteronen 0.5, 0.75 and 1.0mg and ethinylestradiol 0.035mg)  will be discontinued at the end of January 2016; Ovysmen (norethisterone 0.5mg and ethinylestradiol 0.035mg) in April 2016, Binovum (norethisterone 0.5mg, 1.0mg and ethinylestradiol 0.035mg) in June 2016. This is not due to any safety concerns.

  • Ventmax discontinued Subscription

    17 DEC 2015 15:40

    Ventmax (salbutamol; Chiesi) SR 4mg capsules are no longer in the supply chain and the expiry date of the last stock supplied was 30 November 2015. Ventmax SR 8mg capsules are also being discontinued.

  • Fuzeon product update Subscription

    17 DEC 2015 15:38

    The summary of product characteristics of the HIV medication Fuzeon (enfuvirtide; Roche) powder for solution for injection has been updated to warn that as a peptide, enfuvirtide can cause cutaneous amyloidosis at the injection site.

  • Researchers have found that the high-dose flu vaccine Fluzone, delivered with a booster injection 30 days later, can significantly reduce the rate of flu in patients with plasma cell disorders such as multiple myeloma (HE stain pictured)

    High-dose flu vaccine with booster cuts flu rate in plasma cell disorder patients Subscription

    17 DEC 2015 15:08

    Yale research shows high-dose vaccine Fluzone reduces rate of flu in PCD patients.

  • NICE has rejected the breast cancer drug trastuzumab-emtansine (Kadcyla, Roche) as too expensive for the NHS claiming that it exceeded its cost-effectiveness threshold for routine funding

    Advanced breast cancer drug Kadcyla rejected by NICE Subscription

    17 DEC 2015 13:42

    A drug to treat a type of advanced breast cancer has been rejected for use on the NHS because it is too expensive.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.